Please login to the form below

Olumiant

This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

Lilly reported positive phase II results with its already-approved Olumiant (baricitinib) drug in the skin disorder at last year’s EADV, as did Pfizer with PF-04965842, a more selective

Latest news

Gilead and Galapagos JAK contender scores in RA trial

Another player is Lilly’s Olumiant, though this is held back by safety concerns.
Gilead, Galapagos JAK inhibitor clears phase II test

DVT is a recognised side effect with Eli Lilly’s JAK1 inhibitor Olumiant (baricitinib), which finally made it to market for rheumatoid arthritis in Europe last year but was rejected in ... related. First-to-market JAK inhibitor Xeljanz (tofacitinib)
GSK sells eczema and psoriasis drug to Dermavant for £250m

s Xeljanz (tofacitinib) and Incyte/Eli Lilly’s Olumiant (baricitinib).
Another R&D flop for Incyte, but Jakafi keeps delivering

Nevertheless, it’s another bit of bad news for Incyte after the epacadostat failure, what looks likely to be reduced royalties from Eli Lilly for rheumatoid arthritis JAK inhibitor Olumiant (baricitinib)
AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

be an under-estimate given that a third JAK inhibitor - Eli Lilly and Incyre’s Olumiant (baricitinib) - has been dogged by regulatory problems. ... Olumiant was finally approved by the FDA for RA a couple of weeks ago, but has been saddled with a black

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Medical Writer: Salary TBC

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Programme/ Account Director - Healthcare PR - London: Salary TBC

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Senior Account Director – Healthcare Advertising – London: Salary TBC

Scientific Director – Medical Communications: Salary TBC

EU Head of Business Development and Client Service: Exceptional packge and bonus

Account Director, Healthcare Marketing Agency: Salary TBC

Home-based Senior Medical Writer – Med Ed: Salary TBC

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Medical Education: Salary TBC

Senior Account Manager, Medical Communications, London: Excellent package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Home based, Senior Medical Writer, Medical Communications: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Health Consultant - Brand Comms: Competitive Salary

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Creative/ Medical Writer: Circa £35, 000 With Benefits

Senior Digital Health Specialist – Global Agency: Salary TBC

Home-based Medical Writer – Medical Education: Salary TBC

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Subscribe to our email news alerts

PMHub

Add my company

Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....